Conference Coverage

Adalimumab strikes out for aortic inflammation in psoriasis

Publish date: June 27, 2018

 

REPORTING FROM IID 2018

The work was funded by the National Institutes of Health and AbbVie, adalimumab’s maker. Among many industry ties, Dr. Gelfand is a consultant for Janssen, maker of ustekinumab, and receives research grants from Janssen and AbbVie.

SOURCE: Gelfand JM et al. IID 2018, Abstract 393.

Pages

Recommended Reading

Online psoriasis consultations shown equivalent to office visits
MDedge Internal Medicine
Phase 3 trials show halobetasol/tazarotene lotion works for psoriasis
MDedge Internal Medicine
Xeljanz: FDA panel recommends ulcerative colitis indication
MDedge Internal Medicine
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Internal Medicine
Study using U.K. data quantifies infection risk associated with psoriasis
MDedge Internal Medicine
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
MDedge Internal Medicine
Hidradenitis suppurativa packs mighty QOL impact
MDedge Internal Medicine
Topical corticosteroid-retinoid combination effective in moderate to severe psoriasis
MDedge Internal Medicine
CBC values linked to CVD risk in psoriasis
MDedge Internal Medicine
Psoriasis therapy with biologics not linked to increased cancer risk
MDedge Internal Medicine